Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 12, 1996, Pages 4318-4323

  Pujol, Pascal ^a   Daures, Jean Pierre ^b   Nsakala, Nicole ^a   Baldet, Line ^a   Bringer, Jacques ^a   Jaffiol, Claude ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; PROTIRELIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CELL DIFFERENTIATION; FEMALE; GROWTH INHIBITION; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SURVIVAL RATE; THYROID CANCER; THYROTROPIN RELEASE; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 0029827464     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.12.4318     Document Type: Article

References (28)

1. Ichikawa Y, Saito E, Abe Y, Homma M, Muraki T, Ito K. 1976 Presence of TSH receptor in thyroid neoplasms. J Clin Endocrinol Metab. 42:395-398.
2. Carayon P, Thomas-Morvan C, Castana E, Tubiana M. 1980 Human thyroid cancer: membrane thyrotropin binding and adenylate cyclate activity. J Clin Endocrinol Metab. 51:915-920.
3. Balme HW. 1954 Metastatic carcinoma of the thyroid successfully treated with thyroxine. Lancet. 1:812-813.
4. Staunton MD, Greening WP. 1976 Treatment of thyroid cancer in 293 patients. Br J Surg. 63:253-258.
5. Young RL, Mazzaferri EL, Rahe AJ, Dorfman SG. 1980 Pure follicular thyroid carcinoma: impact of therapy in 214 patients. J Nucl Med. 21:733-737.
6. Mazzaferri EL, Young RJ. 1981 Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 70:511-518.
7. Rossi RL, Cady B, Silverman ML, et al. 1988 Surgically incurable well-differentiated thyroid carcinoma. Prognostic factors and results of therapy. Arch. Surg. 123:569-574.
8. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. 1988 Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Physiol. 14:1063-1075.
9. Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester J, Fremgen A. 1990 Survival discriminants for differentiated cancer. Am J Surg. 160:344-347.
10. Wartofsky L. 1991 Use of sensitive TSH assay to determine thyroid hormone therapy and avoid osteoporosis. Annu Rev Med. 42:341-345.
11. Lamberg BA, Helenius T, Liewendahl K. 1986 Assessment of thyrotropin suppression in thyroid carcinoma patients with a sensitive immunoradiometric TSH assay. Clin Endocrinol (Oxf). 25:259-263.
12. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. 1992 Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 75:344-350.
13. Spencer CA, Lai-Rosenfeld AO, Guttler RB, et al. 1986 Thyrotropin secretion in thyrotoxic and thyroxine-treated patients: assessment by a sensitive immunoenzymometric assay. J Clin Endocrinol Metab. 63:349-355.
14. Wartofsky L. 1993 Does replacement thyroxine therapy cause osteoporosis? Adv Endocrinol Metab. 4:157-175.
15. Biondi B, Fazio S, Carella C, et al. 1993 Cardiacs effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 77:334-338.
16. Sawin CT, Geller A, Wolf PA, et al. 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 331:1249-1252.
17. DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH. 1995 Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab. 80:2946-2953.
18. Crue G, Antunez AR, Esseltyn CB, Hawk WA, Skillern PG. 1985 The advantages of total thyroidectomy and suppression of TSH in the primary treatment of papillary carcinoma of the thyroid. Cancer. 55:2691-2697.
19. Cady B, Cohn K, Rossi RL, et al. 1983 The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery. 94:978-983.
20. Dulgeioff AJ, Hershman JM. 1994 Medical therapy for differentiated thyroid carcinoma. Endocr Rev. 15:500-515.
21. McConahey WM, Hay ID, Woolner LB, Van Heerden JA, Taylor WF. 1986 Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy and outcome. Mayo Clin Proc. 61:978-996.
22. Thoresen SO, Akslen LA, Glattre E, Haldorsen T, Lund EV, Schoultz M. 1989 Survival and prognostic factors in differentiated thyroid cancer: a multivariable analysis of 1,055 cases. Br J Cancer. 59:231-235.
23. Hardy KJ, Walker BR, Lindsay RS, Kennedy RL, Secki JR, Padfield PL. 1995 Thyroid cancer management. Clin Endocrinol (Oxf). 42:651-655.
24. Clark OH. 1981 TSH suppression of thyroid nodules and thyroid cancer. World J Surg. 5:39-46.
25. Grund FM, Niewoehner CB. 1989 Hyperthyroxemia in patients receiving thyroid replacement therapy. Arch Intern Med. 149:921-924.
26. Utiger RD. 1994 Subclinical hyperthyroidism-just a low serum thyrotropin concentration or something more? N Engl J Med. 331:1302-1303.
27. Leese GP, Jung RT, Guthrie C, Waugh N, Browning MCK. 1992 Morbidity in patients on L-thyroxine; a comparison of those with normal TSH to those with a supressed TSH. Clin Endocrinol (Oxf). 37:500-503.
28. Rendell M, Salmon D. 1985 'Chemical hyperthyroidism:' the significance of elevated serum thyroxine levels in L-thyroxine treated individuals. Clin Endocrinol (Oxf). 22:693-700.